Bristol pravastatin/aspirin co-package
Bristol-Myers Squibb's NDA (21-387) for a pravastatin/aspirin co-package (tentatively named Pravaguard) will return to FDA's Cardiovascular & Renal Drugs Advisory Committee for consideration on the afternoon of July 18. The NDA was resubmitted following a Jan. 18 meeting at which the committee voted against approval for long-term management to reduce the risk of cardiovascular events in patients with clinically evident coronary heart disease (1"The Pink Sheet" Jan. 21, p. 7)...
You may also be interested in...
Bristol-Myers Squibb's Pravachol/Bufferin titration inflexibility was cited as a main issue by FDA's Cardiovascular & Renal Drugs Advisory Committee in voting against approval of the fixed-dose combination of the cholesterol-lowering and aspirin products
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.